AN2 THERAPEUTICS, INC.

Insiders AN2 Therapeutics, Inc.

Equities

ANTX

US0373261058

Market Closed - Nasdaq Other stock markets 04:00:00 2024-07-12 pm EDT			5-day change	1st Jan Change
2.58 ^USD	+1.57%		-1.90%	-87.41%

Jul. 05	Leerink Upgrades AN2 Therapeutics to Outperform Rating With $5 Price Target	MT
Jul. 03	Leerink Partners Upgrades AN2 Therapeutics to Outperform From Market Perform, Price Target is $5	MT

Insiders

Unlock all the news: Be the first to know and act before the market!

100% Free Registration

An2 Therapeutics Insider Sold Shares Worth $1,911,410, According to a Recent SEC Filing	Jan. 22	MT
An2 Therapeutics Insider Sold Shares Worth $1,704,513, According to a Recent SEC Filing	23-10-04	MT
An2 Therapeutics Insider Sold Shares Worth $150,708, According to a Recent SEC Filing	23-09-29	MT
Insider Sell: An2 Therapeutics	23-09-08	MT
AN2 Therapeutics, Inc. Announces Executive Changes	23-09-08	CI
AN2 Therapeutics, Inc. Appoints Maggie Fitzpatrick to its Board of Directors	22-05-09	CI
Insider Buy: AN2 Therapeutics	22-04-01	MT
Insider Buy: AN2 Therapeutics	22-04-01	MT
AN2 Therapeutics, Inc. Appoints Patricia Martin and Stephanie Wong to the Board of Directors	22-01-07	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Protect and grow your investments with the help of our experts

Secure my Investments

fermer